Juan Camilo Arjona Ferreira
Chief Tech/Sci/R&D Officer chez ORGANON & CO.
Fortune : 244 $ au 31/03/2024
Profil
Juan Camilo Arjona Ferreira is currently the Chief Medical Officer & Head of R&D at Organon & Co. Prior to his current position, he held the role of Chief Medical Officer at Myovant Sciences Ltd.
from 2017 to 2023.
Before that, he served as the Senior Vice President of Clinical Development at Shionogi, Inc. from 2014 to 2017.
From 2002 to 2014, he worked as the Executive Director of Clinical Research at Merck & Co., Inc. Dr. Arjona Ferreira obtained his graduate degree from Universidad del Rosario in 1993.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
ORGANON & CO.
0,00% | 29/03/2024 | 13 ( 0,00% ) | 244 $ | 31/03/2024 |
Postes actifs de Juan Camilo Arjona Ferreira
| Sociétés | Poste | Début |
|---|---|---|
| ORGANON & CO. | Chief Tech/Sci/R&D Officer | 05/09/2023 |
Anciens postes connus de Juan Camilo Arjona Ferreira
| Sociétés | Poste | Fin |
|---|---|---|
| MYOVANT SCIENCES LTD. | Chief Tech/Sci/R&D Officer | 01/05/2023 |
Shionogi, Inc.
 Shionogi, Inc. Pharmaceuticals: MajorHealth Technology Part of Shionogi & Co., Ltd., Shionogi, Inc. is a pharmaceutical company based in Florham Park, NJ. Since 1878, the private company has been utilizing science to address health challenges and has discovered several novel antibiotics and medications for HIV and influenza. Shionogi conducts ongoing research into established products and new antibiotic compounds, as well as developing an investigational antiviral for COVID-19. The company is committed to pursuing discovery through partnerships, including collaboration with scientists through investigator-initiated research. Shionogi is dedicated to advancing the greater good by developing, partnering, and commercializing medicine to treat serious unmet medical needs in infectious disease and other areas of high medical need including neurology and cardiovascular disease. Nathan McCutcheon has been the CEO of the company since 2019. | Chief Tech/Sci/R&D Officer | 01/07/2017 |
| MERCK & CO., INC. | Corporate Officer/Principal | 01/03/2014 |
Myovant Sciences, Inc.
 Myovant Sciences, Inc. Medical SpecialtiesHealth Technology Myovant Sciences, Inc. offers therapeutics for women's health and prostate cancer. The company is headquartered in New York, NY. | Corporate Officer/Principal | - |
Formation de Juan Camilo Arjona Ferreira
| Universidad del Rosario | Graduate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| MERCK & CO., INC. | Health Technology |
| ORGANON & CO. | Health Technology |
| Entreprise privées | 3 |
|---|---|
Shionogi, Inc.
Shionogi, Inc. Pharmaceuticals: MajorHealth Technology Part of Shionogi & Co., Ltd., Shionogi, Inc. is a pharmaceutical company based in Florham Park, NJ. Since 1878, the private company has been utilizing science to address health challenges and has discovered several novel antibiotics and medications for HIV and influenza. Shionogi conducts ongoing research into established products and new antibiotic compounds, as well as developing an investigational antiviral for COVID-19. The company is committed to pursuing discovery through partnerships, including collaboration with scientists through investigator-initiated research. Shionogi is dedicated to advancing the greater good by developing, partnering, and commercializing medicine to treat serious unmet medical needs in infectious disease and other areas of high medical need including neurology and cardiovascular disease. Nathan McCutcheon has been the CEO of the company since 2019. | Health Technology |
Myovant Sciences, Inc.
Myovant Sciences, Inc. Medical SpecialtiesHealth Technology Myovant Sciences, Inc. offers therapeutics for women's health and prostate cancer. The company is headquartered in New York, NY. | Health Technology |
Myovant Sciences Ltd.
 Myovant Sciences Ltd. BiotechnologyHealth Technology Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for the treatment of women's health and endocrine diseases. It offers ORGOVYXTM, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer, and MYFEMBREE, which is taken for the management of heavy menstrual bleeding associated with uterine fibroids. The company was founded on February 2, 2016 and is headquartered in London, the United Kingdom. | Health Technology |
